Results 261 to 270 of about 117,514 (300)
Some of the next articles are maybe not open access.
Overview of Amorphous Solid Dispersion Technologies
2014Successful development of amorphous solid dispersion formulations depends on three primary factors: active pharmaceutical ingredient properties, stabilizing polymer, and the processing technology. Polymer provides the fundamental framework for stabilizing the amorphous form and the process supplies the energy required to transform the system into an ...
Harpreet Sandhu +3 more
openaire +1 more source
Diffusivity of amorphous drug in solid dispersion
Journal of Thermal Analysis and Calorimetry, 2013Filmy solid dispersion of terfenadine (TFD), fenofibrate (FFB), and carbamazepine (CBZ) and methacrylic acid methyl methacrylate copolymer (Eudragit®) was prepared by evaporating their solution. Raman and IR measurements for the filmy samples were performed.
Etsuo Yonemochi +3 more
openaire +1 more source
Anomalous transit-time dispersion in amorphous solids
Physical Review B, 1975Measurements of the transient photocurrent $I(t)$ in an increasing number of inorganic and organic amorphous materials display anomalous transport properties. The long tail of $I(t)$ indicates a dispersion of carrier transit times. However, the shape invariance of $I(t)$ to electric field and sample thickness (designated as universality for the classes
Harvey Scher, Elliott W. Montroll
openaire +1 more source
Characterization of amorphous solid dispersions: An update
Journal of Drug Delivery Science and Technology, 2019Abstract Amorphous solid dispersions (ASDs) are a promising formulation approach to improve the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs. ASDs have complicated physicochemical properties due to the various formulations and processes used to produce them. These properties influence their physical stability, so it
Xiangyu Ma, Robert O. Williams
openaire +1 more source
Physical Stability Studies of Miscible Amorphous Solid Dispersions
Journal of Pharmaceutical Sciences, 2010Physical stability of 12 amorphous solid dispersions was evaluated over 9-22 months under ambient conditions using X-ray powder diffraction. The nine dispersions initially characterized as miscible drug-polymer systems all remained X-ray amorphous for the duration of their respective studies.
openaire +2 more sources
Theoretical Considerations in Developing Amorphous Solid Dispersions
2014Before pursuing the laborious route of amorphous solid dispersion formulation and development, which is the topic of many of the subsequent chapters in this book, the formulation scientist would benefit from a priori knowledge whether the amorphous route is a viable one for a given drug and how much solubility improvement, and hence increase in ...
Laitinen, Riikka +6 more
openaire +2 more sources
Orodispersible films based on amorphous solid dispersions of tetrabenazine
International Journal of Pharmaceutics, 2017In this work, the formation and stability of amorphous solid dispersions (SDs) as orodispersible films (ODF) were investigated using tetrabenazine (TBZ) as a poorly water soluble drug. The influence of polymer nature and pH-modifier incorporation to form and maintain SDs was investigated. TBZ-loaded ODF were formulated using 4 different polymers (HPMC,
Senta-Loys, Zoé +4 more
openaire +3 more sources
Amorphous Solid Dispersion Using Supercritical Fluid Technology
2014Use of supercritical fluid (SCF) processing technologies in the pharmaceutical industry has seen remarkable growth as an alternate technology for the preparation of micro- and nano-sized particles. Carbon dioxide, having low critical temperature (31.2 °C) and pressure (73.8 bar or 7.4 Mpa) and being nonflammable, nontoxic, and environmentally safe, is ...
Pratik Sheth, Harpreet Sandhu
openaire +1 more source
Ternary Amorphous Solid Dispersions
Journal of Developing Drugs, 2017Dev Prasad +3 more
openaire +1 more source
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Ca-A Cancer Journal for Clinicians, 2021Michael L Cheng +2 more
exaly